16 March 2007
Results of liver transplantation for hepatocellular cancer
Krzysztof Zieniewicz, Waldemar Patkowski, Paweł Nyckowski, Abdulsalam Alsharabi, Bogdan Michałowicz, Jacek Pawlak, Rafał Paluszkiewicz, Tadeusz Wróblewski, Bogusław Najnigier, Piotr Smoter, Piotr Hevelke, Anna Skwarek, Piotr Remiszewski, Marcin Kotulski, Michał Skalski, Leszek Pączek, Marek KrawczykAnn Transplant 2007; 12(1): 11-14 :: ID: 495357
Abstract
Background: Liver transplantation (LTx) for hepatocellular carcinoma (HCC) in cirrhotic liver is nowadays generally accepted treatment modality.
Aim of Study: Overview of the indications and results of the LTx in the patients with HCC, the first one performed in 2001.
Material/Methods: Among 357 adult liver transplant recipients in the period 1994–04.2005, in 26 (7%) the indication was HCC (16 men: 10 women, age 20–65, mean 46.5 years). HCC developed in cirrhotic liver in 25 pts. 12 (48%) were Child C, 10 (30%) – Child B and 3 (12%) – Child A patients. As underlying disease in 2 patients (8%) was alcoholic cirrhosis, in 7 (28%) – HBV cirrhosis, in 12 (48%) – HCV cirrhosis and in 4 (16%) – HBV/HCV cirrhosis. Milano criteria were met in 20 patients (77%). The mean waiting list time was 2.9 months (range 1–6 months). Seven patients underwent liver resection and 1 transarterial chemoembolization prior to LTx. 11 patients (42%) were operated on with use of veno-venous bypass, in 15 patients (58%) the piggy back technique was applied. Rapamycine based immunosuppression was preferred in post-LTx treatment.
Results: Operative mortality was 0. 4 patients required relaparotomy for intraperitoneal bleeding. 21 patients (81%) are alive in good general condition, 19 – free of the disease. 5 patients died 7–28 months after LTx (mean 16.7). The mean survival time is 20 months (range 1–38).
Conclusions: Liver transplantation is safe and effective method of treatment of the selected patients with HCC in cirrhotic liver. Further investigations concerning the precise indications, timing of the transplantation and adjuvant treatment are necessary.
Keywords: liver transplantation (LTX), Hepatocellular carcinoma (HCC)
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






